Citations

Showing 10 of 108083 citations.

Clinical Significance of Anti–U1 Ribonucleoprotein Antibody Is Analyte Dependent: Implications for Laboratory Reporting, Interpretation, and Interassay Correlations
Tebo, Anne E. , Peterson, Lisa K. , Snyder, Melissa R. , Lebiedz‐Odrobina, Dorota

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 10, 2023 | Volume: 147 | Issue: 12 | Pages: 1461-1465

10.5858/arpa.2022-0316-oa | PMID 36897998 Get It

Context.— Antibodies to U1 ribonucleoprotein (U1RNP) were first described more than 50 years ago, and although clinically relevant for antinuclear antibody–associated connective tissue disease (ANA-CTD), test results are challenging to interpret. Objective.— To evaluate the impact of anti-U1RNP analyte diversity in the assessment of patients at risk for ANA-CTD. Design.— Two multiplex assays for U1RNP (Smith [Sm]/RNP and RNP68/A) were used to test serum specimens from consecutive patients (n = 498) under evaluation for CTD in a single academic center. Discrepant specimens were further tested for Sm/RNP antibody by enzyme-linked immunosorbent assay and the BioPlex multiplex assay. Data were evaluated for antibody positivity per analyte and their method of detection, correlations between analytes, and impact on clinical diagnoses through retrospective chart review. Results.— Of the 498 patients tested, 47 (9.4%) were positive in the RNP68/A (BioPlex) and 15 (3.0%) were positive in the Sm/RNP (Theradiag) immunoassays. U1RNP-CTD, other ANA-CTD, and no ANA-CTD were diagnosed in 34% (16 of 47), 12.8% (6 of 47), and 53.2% (25 of 47) of the cases, respectively. The prevalence of antibody by method in patients with U1RNP-CTD was 100.0% (16 of 16), 85.7% (12 of 14), 81.5% (13 of 16), and 87.5% (14 of 16) for RNP68/A, Sm/RNP BioPlex, Sm/RNP Theradiag, and Sm/RNP Inova, respectively. For other ANA-CTD and no ANA-CTD, the highest prevalence was observed with RNP68/A; all others had comparable performance. Conclusions.— In this study, the overall performance characteristics of Sm/RNP antibody assays were comparable; however, the RNP68/A immunoassay was very sensitive but less specific. In the absence of harmonization, reporting the type of U1RNP analyte in clinical testing may be useful in guiding interpretation and interassay correlations.
Real‐World Outcomes of Endovascular Thrombectomy for Basilar Artery Occlusion: Results of the BArONIS Study
Dicpinigaitis, Alis J. , Dick‐Godfrey, Rosalind, Gellerson, Olivia, Shapiro, Steven D. , Kamal, Haris , Ghozy, Sherief , Yaghi, Shadi , Altschul, David , Brook, Allan , Jovin, Tudor G. , Gandhi, Chirag D. , Yaghi, Shadi , Ghozy, Sherief , Altschul, David J , Jovin, Tudor G , Dick-Godfrey, Rosalind, Kaur, Gurmeen , Desai, Shashvat M. , Ortega-Gutierrez, Santiago , Jadhav, Ashutosh P. , Hassan, Ameer E , Nguyen, Thanh N. , Mayer, Stephan A. , Nogueira, Raul G. , Al‐Mufti, Fawaz

Mayo Clinic

Annals of Neurology | March 10, 2023 | Volume: 94 | Issue: 1 | Pages: 55-60

10.1002/ana.26640 | PMID 36897101 Get It

ObjectiveTo evaluate clinical outcomes of endovascular thrombectomy (EVT) for acute basilar artery occlusion (BAO) using population‐level data from the United States.MethodsWeighted discharge data from the National Inpatient Sample were queried to identify adult patients with acute BAO during the period of 2015 to 2019 treated with EVT or medical management only. Complex samples statistical methods and propensity‐score adjustment using inverse probability of treatment weighting (IPTW) were performed to assess clinical endpoints.ResultsAmong 3,950 BAO patients identified, 1,425 (36.1%) were treated with EVT [mean age 66.7 years, median National Institute of Health Stroke Scale (NIHSS) score 22]. On unadjusted analysis, 155 (10.9%) EVT patients achieved favorable functional outcomes (discharge disposition to home without services), while 515 (36.1%) experienced in‐hospital mortality, and 20 (1.4%) developed symptomatic intracranial hemorrhage (sICH). Following propensity‐score adjustment by IPTW accounting for age, stroke severity, and comorbidity burden, EVT was independently associated with favorable functional outcome [adjusted odds ratio (aOR) 1.25, 95% confidence interval (CI) 1.07, 1.46; p = 0.004], but not with in‐hospital mortality or sICH. In an IPTW‐adjusted sub‐group analysis of patients with NIHSS scores >20, EVT was associated with both favorable functional outcome (discharge disposition to home or to acute rehabilitation) (aOR 1.55, 95% CI 1.24, 1.94; p < 0.001) and decreased mortality (aOR 0.78, 95% CI 0.69, 0.89; p < 0.001), but not with sICH.InterpretationThis retrospective population‐based analysis using a large national registry provides real‐world evidence of a potential benefit of EVT in acute BAO patients. ANN NEUROL 2023;94:55–60
How closely are outcome questionnaires correlated to patient satisfaction after cervical spine surgery for myelopathy?
Zaki, Mark M. , Joshi, Rushikesh S. , Ibrahim, Sufyan , Michalopoulos, Giorgos D. , Linzey, Joseph R. , Saadeh, Yamaan S. , Upadhyaya, Cheerag D., Coric, Domagoj , Potts, Eric A. , Bisson, Erica F. , Turner, Jay D. , Knightly, John J. , Fu, Kai-Ming, Foley, Kevin T. , Tumialán, Luis M. , Shaffrey, Mark E., Bydon, Mohamad , Mummaneni, Praveen V. , Chou, Dean , Chan, Andrew K. , Meyer, Scott A., Asher, Anthony L. , Shaffrey, Christopher I. , Gottfried, Oren N., Than, Khoi D. , Wang, Michael , Haid, Regis W., Slotkin, Jonathan R., Glassman, Steven D. , Park, Paul , Ibrahim, Sufyan , Michalopoulos, Giorgos , Wang, Michael

Mayo Clinic

Journal of Neurosurgery: Spine | March 10, 2023 | Volume: 38 | Issue: 5 | Pages: 521-529

10.3171/2023.1.spine22888 | PMID 36805998 Get It

OBJECTIVE Patient-reported outcomes (PROs) have become the standard means to measure surgical outcomes. Insurers and policy makers are also increasingly utilizing PROs to assess the value of care and measure different aspects of a patient’s condition. For cervical myelopathy, it is currently unclear which outcome measure best reflects patient satisfaction. In this investigation, the authors evaluated patients treated for cervical myelopathy to determine which outcome questionnaires best correlate with patient satisfaction. METHODS The Quality Outcomes Database (QOD), a prospectively collected multi-institutional database, was used to retrospectively analyze patients undergoing surgery for cervical myelopathy. The North American Spine Society (NASS) satisfaction index, Neck Disability Index (NDI), numeric rating scales for neck pain (NP-NRS) and arm pain (AP-NRS), EQ-5D, and modified Japanese Orthopaedic Association (mJOA) scale were evaluated. RESULTS The analysis included 1141 patients diagnosed with myelopathy, of whom 1099 had an NASS satisfaction index recorded at any of the follow-up time points. Concomitant radiculopathy was an indication for surgery in 368 (33.5%) patients, and severe neck pain (NP-NRS ≥ 7) was present in 471 (42.8%) patients. At the 3-month follow-up, NASS patient satisfaction index scores were positively correlated with scores for the NP-NRS (r = 0.30), AP-NRS (r = 0.32), and NDI (r = 0.36) and negatively correlated with EQ-5D (r = −0.38) and mJOA (r = −0.29) scores (all p < 0.001). At the 12-month follow-up, scores for the NASS index were positively correlated with scores for the NP-NRS (r = 0.44), AP-NRS (r = 0.38), and NDI (r = 0.46) and negatively correlated with scores for the EQ-5D (r = −0.40) and mJOA (r = −0.36) (all p < 0.001). At the 24-month follow-up, NASS index scores were positively correlated with NP-NRS (r = 0.49), AP-NRS (r = 0.36), and NDI (r = 0.49) scores and negatively correlated with EQ-5D (r = −0.44) and mJOA (r = −0.38) scores (all p < 0.001). CONCLUSIONS Neck pain was highly prevalent in patients with myelopathy. Notably, improvement in neck pain–associated disability rather than improvement in myelopathy was the most prominent PRO factor for patients. This finding may reflect greater patient concern for active pain symptoms than for neurological symptoms caused by myelopathy. As commercial payers begin to examine novel remuneration strategies for surgical interventions, thoughtful analysis of PRO measurements will have increasing relevance.
Next Steps Toward Reducing Surgical Morbidity After Complex Cytoreductive Surgery in Fit Surgical Patients
Warring, Simrit K. , Weaver, Amy L. , McGree, Michaela E. , Cliby, William A. , Narasimhulu, Deepa Maheswari , Kumar, Amanika , Langstraat, Carrie

Mayo Clinic

Journal of Gynecologic Surgery | March 10, 2023 | Volume: 39 | Issue: 3 | Pages: 123-129

10.1089/gyn.2022.0114 Get It

Objective: Using a triage algorithm for primary cytoreductive surgery (PCS) reduces perioperative mortality, however, nonlethal complications are common. This study identified procedures associated with postoperative complications in triage-appropriate women, with the aim of guiding the next steps to foster surgical quality improvement. Materials and Methods: Consecutive triage-appropriate women with stage IIIC/IV ovarian cancer undergoing PCS, from January 2012 to April 2018, were included. The expanded Accordion scale was used to grade complications. Adjusted risk ratios ( RRs ) were calculated to quantify the association between concomitant procedures and risk of 30-day grade 3+ (G3+) complications by fitting Poisson regression models adjusted for performance status and age. Population-attributable risk (PAR) was calculated based on the adjusted RR s and prevalence of each procedure. Results: Of 214 women, 82.7% had intermediate- or high-complexity surgery, 68.7% had complete gross resection, 3.7% had residual disease >1 cm, and 18.7% experienced G3+ complications. In univariate analysis, operative time, surgical complexity, splenectomy, and bowel resection (any and extent of) were associated with G3+ complications. Operative time, bowel resection (any, extent of, and large) were associated with G4+ complications. In the adjusted analysis for G4+ complications, bowel resection (any, extent of, and large) had statistically significant PAR values of 60.7%, 54.7%, and 50.8%, respectively. PAR values associated with G3+ complications were 27.4% and 26.8% for any and multiple bowel resections, respectively. Conclusions: Bowel resection, upper abdominal procedures, and longer operative times are essential for PCS, but each contributes to the relatively constant rates of postoperative morbidity despite triage to prevent frail patients from undergoing PCS. Surgical-improvement research should focus on improving the safety of these procedures. (J GYNECOL SURG 39:123)
A swine model of pulmonary embolism with human-derived thrombi
Larco, Jorge Luis Arturo, Abbasi, Mehdi , Yasin, Omar , Vadlamudi, Venu, Larco, Jorge Arturo , Madhani, Sarosh Irfan , Liu, Yang , Shahid, Adnan Hussain , Moreno, Cristina , Savastano, Luis

Mayo Clinic

American Journal of Interventional Radiology | March 10, 2023 | Volume: 7 | Issue: No issue available | Pages: 6

10.25259/ajir_31_2022 Get It

Objectives: The development and evaluation of percutaneous thrombectomy devices for pulmonary embolism (PE) pose a need for standardized large in vivo models with representative anatomical and physiological conditions and clots analogs. In this study, we present a swine model of PE model employing human-derived clot analogs. Material and Methods: Baseline angiographic and physiological pressure measurements were obtained in six adult Yorkshire pigs (45–65 kg) and results were benchmarked for interspecies comparison with published human data using fluoroscopic examinations, intra-arterial pressure measurements, and histologic studies. Then, clot analogs were created ex vivo employing banked human blood and a subset incubated in iodinated contrast for fluoroscopic visualization. Clot analogs were then embolized via a femoral venous access and angiographic/physiological consequences were evaluated. Results: The main, right, and left pulmonary artery diameters were 24 ± 1.1 mm, 16.5 ± 0.8 mm, and 12.6 ± 1.2 mm, respectively. The angle between the main pulmonary artery at the bifurcation point was approximately 90–95°. The clot analogs were heterogeneous and had increased fibrin content along the clot length. The overall composition was 96.63% red blood cell (RBC)/3.37% fibrin in the initial section, 48.85% RBC/51.15% fibrin in the intermediate section, and 3.44% RBC/96.56% fibrin in the final section. Embolization of the clot analogs resulted in distal occlusion of the right and left pulmonary arteries. Conclusions: This swine model coupled with clot analog is able to accurately mimic human anatomical and physiological conditions in PE making it feasible for the evaluation of pulmonary thrombectomy devices.
Definitive Closure of the Patent Ductus Arteriosus in Preterm Infants and Subsequent Short-Term Respiratory Outcomes
Wheeler, Craig R , Vogel, Elizabeth R. , Cusano, Michael A, Friedman, Kevin G. , Ibla, Juan C. , Vogel, Elizabeth R , Callahan, Ryan M. , Porras, Diego , Levy, Philip Thaler

Mayo Clinic

Respiratory Care | March 10, 2023 | Volume: 67 | Issue: 5 | Pages: 594-606

10.4187/respcare.09489 | PMID 35473850 Get It

A persistent patent ductus arteriosus (PDA) can have significant clinical consequences in preterm infants, depending on the degree of left-to-right shunting, its impact on cardiac performance, and associated perinatal risk factors that can mitigate or exacerbate the shunt. Although the best management strategy remains contentious, PDAs that have contraindications to, or have failed medical management have historically undergone surgical ligation. Recently smaller occluder devices and delivery systems have allowed for minimally invasive closure in the catheterization laboratory even in extremely premature infants. The present review summarizes the pathophysiologic manifestations, treatment options and management of hemodynamically significant PDA in preterm infants. Additionally, we review the available literature surrounding the respiratory support and outcomes of preterm infants following definitive PDA closure.
COL1A1 and COL1A2 variants in Ehlers‐Danlos syndrome phenotypes and COL1‐related overlap disorder
Venable, Elise R. , Thoreson, Emily , Baudhuin, Linnea M. , Venable, Elise, Thoreson, Emily K, Knight, Dacre R T

Mayo Clinic

American Journal of Medical Genetics Part C: Seminars in Medical Genetics | March 10, 2023 | Volume: 193 | Issue: 2 | Pages: 147-159

10.1002/ajmg.c.32038 | PMID 36896471 Get It

AbstractPathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers‐Danlos syndrome (EDS) subtypes and OI‐EDS overlap syndromes (OIEDS1 and OIEDS2, respectively). Here we describe a cohort of 34 individuals with likely pathogenic and pathogenic variants in COL1A1 and COL1A2, 15 of whom have potential OIEDS1 (n = 5) or OIEDS2 (n = 10). A predominant OI phenotype and COL1A1 frameshift variants are present in 4/5 cases with potential OIEDS1. On the other hand, 9/10 potential OIEDS2 cases have a predominant EDS phenotype, including four with an initial diagnosis of hypermobile EDS (hEDS). An additional case with a predominant EDS phenotype had a COL1A1 arginine‐to‐cysteine variant that was originally misclassified as a variant of uncertain significance despite this type of variant being associated with classical EDS with vascular fragility. Vascular/arterial fragility was observed in 4/15 individuals (including one individual with an original diagnosis of hEDS), which underscores the unique clinical surveillance and management needs in these patients. In comparison to previously described OIEDS1/2, we observed differentiating features that should be considered to refine currently proposed criteria for genetic testing in OIEDS, which will be beneficial for diagnosis and management. Additionally, these results highlight the importance of gene‐specific knowledge for informed variant classification and point to a potential genetic resolution (COL1A2) for some cases of clinically diagnosed hEDS.
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease
Caldera, Freddy , Spaulding, Aaron , Moriarty, Jim, Zhu, Ye , Spaulding, Aaron C. , Spaulding, Aaron , Caldera, Freddy , Borah, Bijan J. , Hayney, Mary S. , Farraye, Francis A.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 10, 2023 | Volume: 57 | Issue: 11 | Pages: 1326-1334

10.1111/apt.17454 | PMID 36896952 Get It

Summary Background Recombinant zoster vaccine (RZV) is recommended for all adults ≥19 years of age who are at increased risk for HZ, including patients with inflammatory bowel disease (IBD). Methods A Markov model was constructed to compare the RZV cost‐effectiveness with no vaccination in patients with Crohn's Disease (CD) and ulcerative colitis (UC). A simulated cohort of 1 million patients was used for each IBD group at ages 18, 30, 40, and 50. The primary objective of this analysis was to compare RZV cost‐effectiveness in patients with CD and UC, comparing vaccination to no vaccination. Results Overall, vaccination is cost‐effective for both CD and UC, with the incremental cost‐effectiveness ratio (ICERs) below $100,000/quality‐adjusted life years (QALY) for all age cohorts. For patients with CD, 30 years of age and older, and those with UC 40 years and older, vaccination was both more effective and less expensive than the non‐vaccinated strategy (CD ≥30: ICERs $6183–$24,878 and UC ≥40: ICERs $9163–$19,655). However, for CD patients under 30 (CD 18: ICER $2098) and UC patients under 40 (UC = 18: ICER $11,609, and UC = 30: $1343), costs were greater for vaccinated patients, but there was an increase in QALY. One‐way sensitivity analysis of age indicates that cost break‐even occurs at age 21.8 for the CD group and 31.5 for the UC group. In probabilistic sensitivity analysis, 92% of both CD and UC simulations indicated that vaccination was preferred. Conclusion In our model, vaccination with RZV was cost‐effective for all adult patients with IBD.
Antisynthetase syndrome with predominant lung involvement. An easy to miss diagnosis
Tzilas, Vasilios , Ryu, Jay H. , Sfikakis, Petros P. , Τzouvelekis, Αrgyris , Bouros, Demosthenes , Ryu, Jay H

Mayo Clinic

Pulmonology | March 10, 2023 | Volume: 29 | Issue: 4 | Pages: 271-272

10.1016/j.pulmoe.2023.02.009 | PMID 36906463 Get It